Aadi Bioscience Inc - AADI Quarterly EPS earnings growth

Corporate company logo of Aadi Bioscience Inc (AADI)

The quarterly EPS change reflects the impact of commercialization risks for the primary sarcoma drug, with the current figure standing at 23.30. Aadi Bioscience (AADI) develops nanoparticles for the targeted suppression of the mTOR pathway in oncology. The company generates revenue from the sale of drugs against rare malignant neoplasms that target protein markers.

aadibio.com (AADI) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 03/19/2025

Analytical breakdowns for Aadi Bioscience

- share price and consensus valuation forecast:
Stock Quotes aadibio.com|AADI - Analyst Forecast Prices
- issuer market value details:
Market Capitalization Aadi Bio|AADI - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Aadi Bioscience|AADI - Accounting Value of Company|Market Capitalization to Book Value Ratio aadibio.com|AADI - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital Aadi Bioscience|AADI - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio aadibio.com|AADI - Company Cumulative Indebtedness|Debts to Book Capitalization Aadi Bio|AADI - Long-Term Debt|Company Short-Term Debts Aadi Bioscience|Quick Liquidity Indicator aadibio.com
- earnings and market multiples details:
AADI - Final Profit|Future Profit Aadi Bioscience|AADI - Market Price to Net Income Ratio|Forward P/E Multiple aadibio.com|AADI - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Aadi Bio|AADI - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Aadi Bioscience|AADI - Earnings per share for the trailing year|Quarterly EPS earnings growth aadibio.com|AADI - Earnings growth in current year|Net earnings per share growth forecast for next year Aadi Bioscience
Fundamental company valuation:Aadi Bioscience Inc - AADI
Flagship merchandise of Aadi Bioscience, Inc.

Earnings per share dynamics measure the rate of change in net income, reflecting operational efficiency and capital sensitivity to global liquidity. Given Aadi Bioscience (AADI) dependence on FDA approvals, the quarterly EPS growth trajectory serves as an indicator of patient base expansion in target oncology, where a one hundred percent client retention rate converts directly into the fundamental growth of the asset's value.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Kymera Corp|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ORIC (ORIC Pharmaceuticals, Inc.)|Net earnings per share growth for the trailing year Relay Therapeutics Inc|Nurix Pharma - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tyra Corp|VSTM (Verastem, Inc.) - Year-over-year net earnings per share growth for the last 12 months|GLUE: Year-over-year earnings per share growth rate for the last twelve months|CGEM (Cullinan Therapeutics, Inc.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immuneering Corp IMRX|Quarterly EPS earnings growth CCCC|Black Diamond Therapeutics, Inc - Year-over-year earnings per share growth for the last 12 months|Repare Therapeutics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months PMVP|KPTI: Year-over-year net earnings per share growth for the last 12 months|Propanc Biopharma Inc - Year-over-year earnings per share growth rate for the last twelve months|BGMS: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)